PLSE Earnings Prediction
The chart below shows how PLSE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PLSE sees a +6.81% change in stock price 10 days leading up to the earnings, and a -0.92% change 10 days following the report. On the earnings day itself, the stock moves by -1.23%. This data can give you a slight idea of what to expect for the next quarter's release.
PLSE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.21
-10.53%
5.00%
No Data Available
PLSE Earnings Analysis
Pulse Biosciences, Inc Common Stock (DE) Corporation (PLSE.O) Earnings Conference Call
Positive
Q3 Business Advancements: The third quarter was extremely productive for Pulse Biosciences, with significant advancements in our business progress since the start of Q3.
First Patients Treated with Nano-PFA: We treated the first patients with AF using our nano-PFA Cardiac Surgical System in Europe.
FDA Breakthrough Device Designation: The Cardiac Surgical System also received U.S. FDA breakthrough device designation for the treatment of AF and was enrolled in FDA's TAP program, which is shorter for Total Product Life Cycle Advisory Program.
Rights Offering Success: We completed our rights offering, raising $60 million in gross proceeds with the potential to raise an additional $66 million through the exercise of warrants.
Cash and Cash Equivalents Increase: As of September 30, 2024, cash and cash equivalents totaled $79 million compared to $44.4 million as of December 31, 2023.
Negative
GAAP Costs Increase: Total GAAP costs and expenses increased by $2.4 million to $13.7 million compared to $11.3 million in the prior year period.
Stock-Based Compensation Increase: The increase in GAAP costs and expenses was primarily driven by an increase in non-cash stock-based compensation expense, which was $3 million in the third quarter of 2024 compared to $1.8 million in the prior year period.
Non-GAAP Cost Increase: Total non-GAAP costs and expenses in the third quarter of 2024 increased by $1.2 million to $10.4 million compared to $9.2 million in the prior year period.
Quarterly Net Loss Comparison: GAAP net loss in the third quarter of 2024 was $12.7 million compared to $10.6 million in the prior year period.
Quarterly Non-GAAP Net Loss: Non-GAAP net loss in the third quarter of 2024 was $9.4 million compared to $8.5 million in the prior year period.
PLSE FAQs
How does PLSE typically perform around its earnings report dates?
Is Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PLSE Earning Call Sentiment
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PLSE.O
-0.86%Positive
The earnings call presents a mixed picture. While there are positive developments in product development and market expansion, the financial health shows increased costs and net loss. The absence of Q&A insights leaves uncertainties unaddressed. The strategic focus on nano-PFA technology and potential market opportunities are positives, but regulatory and competitive risks remain. The rights offering boosts financial stability, but the lack of immediate revenue from clinical trials suggests a neutral stock price movement.